Megin Oy

MEGIN Oy is a global leader in magnetoencephalography (MEG) technology for functional neuroimaging. The company develops and markets MEG Maps™, an integrated end-to-end solution powered by TRIUX™ neo hardware and MEG review™ software, designed for presurgical evaluation, clinical neurology, neurosurgery, and neuroscience research. MEG technology detects small magnetic fields generated by active brain cells, enabling real-time, non-invasive localization of brain activity to within centimeters or millimeters. MEGIN's systems are non-invasive, silent, radiation-free, and unaffected by skull properties or hemodynamic confounds, offering advantages over traditional fMRI and other functional imaging modalities. The TRIUX™ neo represents an advanced acquisition system with improved signal-to-noise ratios and advanced signal analysis capabilities. MEG Maps™ integrates scan acquisition, database management, and analysis functionality for clinical workflows. The company's solutions are deployed in hospitals and research institutions worldwide, including Mayo Clinic, Amsterdam UMC, Boys Town National Research Hospital, and major research centers. Applications include presurgical mapping for epilepsy and tumor surgery, epilepsy diagnosis and monitoring, brain tumor assessment, traumatic brain injury evaluation, stroke research, neurodegenerative disease investigation (Parkinson's, dementia), PTSD research, and pharmaceutical Phase I/III drug development. MEGIN serves neurology, neurosurgery, oncology, psychiatry, and neuroscience research markets globally.